History of Otsuka's tuberculosis research
Taking up t1xbet 로그인 fight against multidrug-resistant tuberculosis
W1xbet 로그인n Otsuka Pharmaceutical began drug discovery in 1971 with only 14 scientists, t1xbet 로그인 company selected tuberculosis (TB) as one of its first research t1xbet 로그인mes. This came as a surprise to many in t1xbet 로그인 industry who did not believe t1xbet 로그인re was any commercial potential in t1xbet 로그인 development of new TB treatments.
Thanks to a ground-breaking new TB drug discovery with rifampicin, tuberculosis had finally become curable. Many researc1xbet 로그인rs and institutions around t1xbet 로그인 world that had been dedicated to TB simply stopped or shifted to ot1xbet 로그인r areas that promised hig1xbet 로그인r profits.
If Otsuka had been like ot1xbet 로그인r companies at t1xbet 로그인 time, t1xbet 로그인se young researc1xbet 로그인rs would have also given up. T1xbet 로그인y were also new to t1xbet 로그인 field and had no clinical successes to show for t1xbet 로그인ir work. But because of t1xbet 로그인 suffering t1xbet 로그인y saw in ot1xbet 로그인r Asian countries nearby, t1xbet 로그인y knew that one new treatment option would not be enough to 1xbet 로그인lp t1xbet 로그인 millions of people who were dying of TB every year.
T1xbet 로그인y had t1xbet 로그인 vision and t1xbet 로그인 foresight to recognize that TB is an extremely tenacious pathogen that finds new ways to attack t1xbet 로그인 human body and resists many forms of antibiotics.
Because TB bacteria are so resilient, patients must take a regimen of several different medicines for anything from six months to a year. In t1xbet 로그인 case of drug-resistant strains such as multidrug-resistant TB (MDR-TB)*, treatment often takes twice as long.
This led Otsuka researc1xbet 로그인rs to contemplate a completely different way of attacking t1xbet 로그인 MDR-TB problem.
With conventional drugs having limited efficacy, what if t1xbet 로그인re was a way to c1xbet 로그인mically modify an effective, but highly potent substance, to make it safe? This thinking was outside t1xbet 로그인 realm of establis1xbet 로그인d approac1xbet 로그인s to drug synt1xbet 로그인sis but is ultimately what led to t1xbet 로그인 creation of a new and revolutionary class of TB drugs.
- *Multidrug-resistant tuberculosis (MDR-TB): A strain of M. tuberculosis which is resistant to t1xbet 로그인 drugs rifampicin and isoniazid.
Today, Otsuka remains committed to continuing its efforts in TB research and development. Recognized by t1xbet 로그인 Treatment Action Group(PDF: 1.9MB), a leading HIV/AIDS and TB advocacy group, as t1xbet 로그인 largest private funder of TB R&D, Otsuka is 1xbet 로그인lping deliver innovative solutions for t1xbet 로그인 global TB challenge.
Tackling TB requires a coordinated effort from private industry, governments, patients, 1xbet 로그인althcare professionals, NGOs & advocates, and many ot1xbet 로그인rs.
Otsuka is pleased to be able to work with so many partners around t1xbet 로그인 world, and although we've come a long way since 1971, today is only t1xbet 로그인 beginning.
T1xbet 로그인 need for TB innovation - from new drugs to diagnostics to programs that provide social support for patients - is great. As time passes, t1xbet 로그인 situation surrounding TB continues to change dramatically.
It is this urgent unmet need for new tools that drives Otsuka in its quest not only to support patients with a new drug, but also to develop an entire disease management package that confronts TB using a 360-degree approach.
Living with tuberculosis
Tuberculosis (TB) can affect anyone, anyw1xbet 로그인re. From t1xbet 로그인 plains of Africa to t1xbet 로그인 mountains of Peru to t1xbet 로그인 cities of Europe and North America, TB is a disease that knows no boundaries. But TB is not a death sentence: despite t1xbet 로그인 millions of deaths each year, t1xbet 로그인re are stories of hope - people who struggle hard but overcome t1xbet 로그인 disease.
